Richard Malabre
Comptroller/Controller/Auditor bei AKEBIA THERAPEUTICS, INC.
Vermögen: 297 854 $ am 30.04.2024
Profil
Richard C.
Malabre is currently the Chief Accounting Officer at Akebia Therapeutics, Inc. Prior to this, he was the Chief Financial Officer & Treasurer at Ultivue, Inc. from 2021 to 2023.
Malabre has a graduate degree from the Massachusetts Institute of Technology and an undergraduate degree from Trinity College (Connecticut).
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.01.2024 | 223 950 ( 0,11% ) | 297 854 $ | 30.04.2024 |
Aktive Positionen von Richard Malabre
| Unternehmen | Position | Beginn |
|---|---|---|
| AKEBIA THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 08.01.2024 |
Ehemalige bekannte Positionen von Richard Malabre
| Unternehmen | Position | Ende |
|---|---|---|
Ultivue, Inc.
 Ultivue, Inc. BiotechnologyHealth Technology Ultivue, Inc. engages in provision of biotechnology services. It offers super-resolution imaging, single-molecule and diagnostics services. Its product Multiplex IHC Reagent Kits, a performance marker multiplexing detection and analysis.The company was founded by Peng Yin, David Walt and Ralf Jumgmann in 2015 and is headquartered in Cambridge, MA. | Finanzdirektor/CFO | 01.09.2023 |
Ausbildung von Richard Malabre
| Massachusetts Institute of Technology | Graduate Degree |
| Trinity College (Connecticut) | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| AKEBIA THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Ultivue, Inc.
Ultivue, Inc. BiotechnologyHealth Technology Ultivue, Inc. engages in provision of biotechnology services. It offers super-resolution imaging, single-molecule and diagnostics services. Its product Multiplex IHC Reagent Kits, a performance marker multiplexing detection and analysis.The company was founded by Peng Yin, David Walt and Ralf Jumgmann in 2015 and is headquartered in Cambridge, MA. | Health Technology |
